PharmaMar Receives $10 Million from Janssen for the Distribution of Yondelis

PharmaMar increases its portfolio. The Spanish pharmaceutical company has announced that it has received $10 million from Janssen upon reaching a commercial milestone established in the licensing agreement related to Yondelis (trabectedin) in the United States. In August 2019, PharmaMar signed a new agreement with the company owned by Johnson & Johnson, which replaced the one from 2001.

Under the old agreement, Janssen reserved the right to exclusively sell and distribute Yondelis in the United States. Currently, the drug is approved in more than seventy countries for the treatment of white tissue sarcoma, and also in some countries for ovarian cancer.

Specifically, Yondelis is a synthetically produced antitumor compound originally isolated from ecteinascidia turbinata, a type of sea squirt. The drug exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are especially dependent.

If you want to read more about PharmaMar and when will start distribution on Yondelis, download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the most important financial news of the day.

The drug that PharmaMar will distribute is approved in more than seventy countries for the treatment of white tissue sarcoma

Last week PharmaMar announced its third-quarter results. In the document, it reported a net profit of €8 million, compared to the €43.4 million it registered in the same period of 2022, a decrease of 82%. In addition, the group recorded total revenues of €117.6 million, compared to the €145.5 million reported in the same period of the previous year.

In fact, the firm assured that “this variation in revenue is mainly due to the introduction into the European market of two generic trabectedin products (Yondelis), which has put significant pressure on prices.” This solution recorded net sales worth €20.5 million until September 2023, compared to €52.2 million in the same period of the previous year.

In the same results, the company wanted to highlight the growth in royalty income,  which rose 8% compared to the same period of the previous year, reaching a total of €38.3 million until September 30th. Mainly, the income came from “our partner Jazz Pharmaceuticals for sales of lurbinectedin in the United States, which were €35.5 million.”

PharmaMar is a biopharmaceutical company based in Madrid, specializing in the discovery, development, and commercialization of new antitumor drugs of marine origin. The company has a presence in Germany, Italy, France, Switzerland, the United Kingdom, Belgium and the United States. 

PharmaMar also has the majority stake in other companies: Genomica, a Spanish company in the field of molecular diagnostics, and Sylentis, dedicated to research into the therapeutic applications of gene silencing (RNAi), among others.

__

(Featured image by pasja1000 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.